The invention provides novel methods for isolating microvesicles from a biological sample and for extracting nucleic acids from the microvesicles.

Embodiments of the invention provide magnetic capture bead mediated methods of molecular barcoding nucleic acid targets of a particle, such as a cell or extracellular vesicle. Aspects of the methods include: a) combining a sample comprising the particle with a magnetic capture bead comprising a capture moiety for the particle to produce a captured sample; b) partitioning captured particles of the captured sample using an applied magnetic field mediated partitioning protocol to produce partitioned captured particles, wherein the partitioned captured particles are in spatial proximity to bead bound barcode nucleic acids comprising target binding regions; and c) lysing the partitioned captured particles so that nucleic acid acids released therefrom bind to the target binding regions to produce captured nucleic acids. Also provided are compositions, e.g., magnetic capture beads, including barcoded magnetic beads, as well as device/systems and kits, that find use in practicing embodiments of the methods.

Embodiments of the invention provide magnetic capture bead mediated methods of molecular barcoding nucleic acid targets of a particle, such as a cell or extracellular vesicle. Aspects of the methods include: a) combining a sample comprising the particle with a magnetic capture bead comprising a capture moiety for the particle to produce a captured sample; b) partitioning captured particles of the captured sample using an applied magnetic field mediated partitioning protocol to produce partitioned captured particles, wherein the partitioned captured particles are in spatial proximity to bead bound barcode nucleic acids comprising target binding regions; and c) lysing the partitioned captured particles so that nucleic acid acids released therefrom bind to the target binding regions to produce captured nucleic acids. Also provided are compositions, e.g., magnetic capture beads, including barcoded magnetic beads, as well as device/systems and kits, that find use in practicing embodiments of the methods.

Provided are vesicles derived from Faecalibacterium prausnitzii and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles in the clinical samples of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease were significantly reduced in comparison with a normal person and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. The vesicles derived from Faecalibacterium prausnitzii according to the subject matter are expected to be usefully employed for the purposes of developing a method for diagnosing gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and/or Parkinson's disease, and a composition for preventing, alleviating, or treating said diseases.

Provided are vesicles derived from Faecalibacterium prausnitzii and to uses thereof. It has been experimentally confirmed by the present inventors that the vesicles in the clinical samples of patients with gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and Parkinson's disease were significantly reduced in comparison with a normal person and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited. The vesicles derived from Faecalibacterium prausnitzii according to the subject matter are expected to be usefully employed for the purposes of developing a method for diagnosing gastric cancer, colorectal cancer, liver cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer, lymphoma, myocardial infarction, atrial fibrillation, and/or Parkinson's disease, and a composition for preventing, alleviating, or treating said diseases.

Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Disclosed herein are methods for assaying a biological sample from a subject by analyzing components of microvesicle fractions in aid of risk, diagnosis, prognosis or monitoring of, or directing treatment of the subject for, a disease or other medical condition in the subject. Also disclosed are methods of treatment and identifying biomarkers using a microvesicle fraction of a subject. Kits, pharmaceutical compositions, and profiles related to the methods are also disclosed.

Methods and kits for isolating tumour-derived exosomes by immunocapture with an anti CA-IX antibody, quantifying tumour-related nucleic acid sequences from the isolated exosomes and determining in vitro the presence of a tumour in a subject are provided.